Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Karolinska Development AB (KDEV) NPV B

Sell:3.80 SEK Buy:3.81 SEK Change: 0.05 SEK (1.33%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:3.80 SEK
Buy:3.81 SEK
Change: 0.05 SEK (1.33%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:3.80 SEK
Buy:3.81 SEK
Change: 0.05 SEK (1.33%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Karolinska Development AB is a Sweden-based investment company. The Company provides capital to biotechnology firms, as well as develops and commercializes biotechnological products. Its activities are involved in a range of areas: oncology, infections and wound healing, women’s health, cardiovascular and hematology, medical equipment, diagnostics, pharmaceutical formulation, as well as implants, among others. The Company’s pharmaceuticals portfolio comprises: AXL1717 for non-small-cell lung carcinoma (NSCLC), APR-246 for ovarian cancer, Sevuparin for malaria, SHACT for pain relief at hysteroscopy and intrauterine device (IUD) insertion, and PC-mAB for acute coronary syndrome (ACS), among others. Furthermore, the Company controls a number of subsidiaries, such as Avaris AB, HBV Thernostica AB, KD Incentive AB, KDev Oncology AB and Limone AB.

Contact details

Tomtebodavagen 23 A
171 65
+46 (8) 52486070

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
653.11 million SEK
Shares in issue:
175.67 million
Stockholm Stock Exchange
Swedish Krona

Key personnel

  • Viktor Drvota
    Chief Executive Officer, Director
  • Tse Ping
    Independent Vice Chairman of the Board
  • Per Aniansson
    Chief Financial Officer, Investment Director
  • Elisabet Gimbringer
    Financial Manager
  • Eva Montgomerie
    Head of Accounting
  • Johan Dighed
    General Counsel
  • Esther Miralles Simo
  • Felicia Rittemar

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.